Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes

Abstract

Oral metformin effectively inhibits DPP IV activity in Type 2 diabetic patients, suggesting that the drug may have potential for future combination therapy with incretin hormones.